Could natural inhibitors of tumor necrosis factor-alpha modify the clinical course of fulminant meningococcemia?
Villard
J
J
Medical Clinic I, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Roux-Lombard
P
P
Hugli
A
A
Dayer
J M
JM
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000097:blood* / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000401:mortality; D003402:Creatine Kinase / Q000097:blood; D005340:Fibrinogen / Q000032:analysis; D006440:Hemofiltration; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008589:Meningococcal Infections / Q000097:blood* / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000401:mortality; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis* / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor; D012016:Reference Values; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis* / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D015850:Interleukin-6; D011956:Receptors, Cell Surface; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D005340:Fibrinogen; D006493:Heparin; D003402:Creatine Kinase